1. Çınar G, Azap Ö. Hematopoietik kök hücre nakli öncesi değerlendirme. Arslan AH, Çınar G, editörler. Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Görülen Enfeksiyonlar. 1. Baskı.
Ankara: Türkiye Klinikleri; 2024. p.1-5.
2. Ljungman, Per. Viral infection after hematopoietic stem cell transplantation. Current Opinion in Hematology 31(6): p 270-274, November 2024. | DOI: 10.1097/MOH.0000000000000833
3. Sureda, A., Carpenter, P.A., Bacigalupo, A. et al. Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic
hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant 59, 832–837 (2024). https://doi.org/10.1038/s41409-024-02251-0
4. Cuvelier GDE, Paulson K, Bow EJ. Updates in hematopoietic cell transplant and cellular therapies that enhance the risk for opportunistic infections. Transpl Infect Dis. 2023; 25(Suppl. 1):
e14101. https://doi.org/10.1111/tid.14101
5. Wu, X., Ma, X., Song, T. et al. The indirect effects of CMV reactivation on patients following allogeneic hematopoietic stem cell transplantation: an evidence mapping. Ann Hematol 103,
917–933 (2024). https://doi.org/10.1007/s00277-023-05509-7
6. Liu YC, Lin TA, Fan NW, et al. Incidence and impact of invasive fungal infection comparing post-transplant cyclophosphamide with cyclosporine plus methotrexate GVHD prophylaxis in
allogeneic HSCT. J Microbiol Immunol Infect. 2025 Apr;58(2):226-232. doi: 10.1016/j.jmii.2024.11.012. Epub 2024 Nov 29. PMID: 39627110.
7. Jimenez Jimenez AM, Spellman SR, Politikos I, et al. Allogeneic Hematopoietic Cell Donor Selection: Contemporary Guidelines from the NMDP/CIBMTR. Transplantation and Cellular
Therapy. 2025. doi: 10.1016/j.jtct.2025.07.004.
8. Nihtilä, J., Penna, L., Salmenniemi, U. et al. Effect of NK cell receptor genetic variation on allogeneic stem cell transplantation outcome and in vitro NK cell cytotoxicity. Sci Rep 14, 26988
(2024). https://doi.org/10.1038/s41598-024-78619-5
9. Sawyer J, Elliott T, Orton L, et al. Prevention and management of acute toxicities from conditioning regimens during hematopoietic stem cell transplantation. Clinical Hematology Internatio-
nal. 2024;6(2):1-10. doi:10.46989/001c.94952. PMID:38817311
10. Neuerburg, Charlotte K.F. et al. Antibiotic Prophylaxis During Allogeneic Stem Cell transplantation,A Comprehensive Single Center Retrospective Analysis. Transplantation and Cellular
Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, Volume 30, Issue 12, 1195-1213.
11. Avenoso, Daniele et al. Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Mye-
lodysplastic Syndrome Patients. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, Volume 29, Issue 11, 698.e1 – 698.
e6
12. Kim, D.H., Shin, DY., Koh, Y. et al. Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical perip-
heral stem cell transplantation. Sci Rep 14, 13885 (2024). https://doi.org/10.1038/s41598-024-64361-5
13. Lazzari L, Catalano G, Bruno A, et al.Post-transplant cyclophosphamide in matched donor transplantation: are we there yet? Curr Res Transl Med. 2025 Apr-Jun;73(2):103499. doi: 10.1016/j.
retram.2025.103499. Epub 2025 Feb 3. PMID: 39923313.
14. Hoeben AW, Saldi S, Aristei C, et al.Rationale, implementation considerations, delineation and planning target objective recommendations for volumetric modulated arc therapy and helical
tomotherapy total body irradiation, total marrow irradiation, total marrow and lymphoid irradiation and total lymphoid irradiation, Radiotherapy and Oncology, Volume 206, 2025, 110822,
ISSN 0167-8140, https://doi.org/10.1016/j.radonc.2025.110822.
15. Bi, Xia. A Tender Reduced-Intensity Conditioning for the Unfit: A Novel 4 Gy Total Body Irradiation-Based Conditioning Followed by Two-Step Haploidentical Stem Cell Transplant, Results
of a Prospective Trial. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, Volume 30, Issue 10, 1009-1011.
16. Niederwieser C, Iacobelli S, Franke GN et al. Reduced intensity versus myeloablative conditioning for MDS: long-term results of an EBMT phase III study (RICMAC). Bone Marrow
Transplant 59, 1084–1091 (2024). https://doi.org/10.1038/s41409-024-02282-7
17. Chen W, Zhao Y, Luo Y, et al. Clinical Characteristics, Microbiology, and Risk Factors for Mortality of Pre-Engraftment and Post-Engraftment Bloodstream Infection in Hematopoietic Stem
Cell Transplantation Recipients. Infect Drug Resist. 2022;15:6893-6905. https://doi.org/10.2147/IDR.S392804
18. Reikvam H, Tsykunova G, Sandnes M, et al. Infectious complications and the utility of serum and cellular markers of infections in the setting of allogeneic hematopoietic stem cell transplan-
tation. Expert Review of Clinical Immunology, 21(3), 291–303. https://doi.org/10.1080/1744666X.2025.2450014
19. Hou LQ, Liu JR, Gu JL, et al. Efficacy of prophylactic antibiotics for the prevention of neutropenic fever in patients with multiple myeloma receiving high-dose cyclophosphamide for stem cell
mobilization. Ann Hematol. 2024 May;103(5):1601-1611. doi: 10.1007/s00277-023-05537-3. Epub 2024 Jan 25. PMID: 38267561; PMCID: PMC11009761.
20. Chung H. CMV infections after HSCT: prophylaxis and treatment. Blood Res. 2025 Jun 3;60(1):33. doi: 10.1007/s44313-025-00081-7. PMID: 40459661; PMCID: PMC12133666.
21. Epstein DJ, Otoukesh S, Shahid Z, et al. Infectious Disease Considerations in Chronic Graft-versus-Host Disease and Transplantation Survivors, Transplantation and Cellular Therapy, Volume
30, Issue 9, Supplement, 2024, S534-S547, https://doi.org/10.1016/j.jtct.2024.05.019.
22. Yeung TW, Chan WYK, Wong SCY, et al. High infection rates and risk-adapted prevention strategies in contemporary pediatric allogeneic hematopoietic stem cell transplantation. Pediatr
Discov. 2024 Jul 14;2(4): e101. doi: 10.1002/pdi3.101. PMID: 40626126; PMCID: PMC12118308.
23. Garg P, Yong KY, Smibert O, et al. The INTERACT study: Infection prevention and surveillance practice in the care of the Australasian cancer and transplant population, American Journal
of Infection Control, 2025, https://doi.org/10.1016/j.ajic.2025.07.008.
24. Stern A, Henig I, Cohen M, et al. Impact of discontinuing routine fluoroquinolone prophylaxis in neutropenic allogeneic haematopoietic stem cell transplant recipients: an observational
study, Journal of Antimicrobial Chemotherapy, Volume 79, Issue 12, December 2024, Pages 3289–3296, https://doi.org/10.1093/jac/dkae360
25. Clerici D, Galli L, Greco R, et al.Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB. Blood Adv. 2023 May
9;7(9):1621-1634. doi: 10.1182/bloodadvances.2022008226. PMID: 36409602; PMCID: PMC10182274.
26. Ohmoto A, Fuji S, Shultes KC, et al. Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia. Bone Marrow Transplant. 2022
Jun;57(6):874-880. doi: 10.1038/s41409-022-01680-z. Epub 2022 Apr 19. PMID: 35440805; PMCID: PMC9017083.
27. Torda A, Chong Q, Lee A, et al. Invasive pneumococcal disease following adult allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2014: 16: 751–759.
28. Hong J, Park HK, Chang SH, et al. A randomized phase II study of acyclovir for the prevention of chemotherapy-induced oral mucositis in patients undergoing autologous hematopoietic stem
cell transplantation. BMC Oral Health. 2023 Dec 15;23(1):1008. doi: 10.1186/s12903-023-03623-6. PMID: 38102638; PMCID: PMC10724996.
29. Sallée L and Boutolleau D. (2024), Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review. Rev
Med Virol, 34: e2574. https://doi.org/10.1002/rmv.2574
30. Karakulska-Prystupiuk E, Feliksbrot-Bratosiewicz M, Król M, et al. Prevalence of VZV Reactivation and Effectiveness of Vaccination with Recombinant Adjuvanted Zoster Vaccine in Alloge-
neic Hematopoietic Stem Cell Recipients—A Single-Center Analysis. Infect. Dis. Rep. 2025, 17, 48. https://doi.org/10.3390/idr17030048
31. Ljungman P, Alain S, Chemaly RF, et al. Recommendations from the 10th European Conference on Infections in Leukaemia for the management of cytomegalovirus in patients after alloge-
neic haematopoietic cell transplantation and other T-cell-engaging therapies. Lancet Infect Dis. 2025 Aug;25(8):e451-e462. doi: 10.1016/S1473-3099(25)00069-6. Epub 2025 Apr 3. PMID:
40188837.
32. Khawaja F, Zamora D and Yong MK et al. American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and
Cellular Therapy RecipientsTransplantation and Cellular Therapy 31 (2025) 727 741.
33. Li WW, Zhang YM, Shen MZ, Mo XD. Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation. Blood Sci. 2024 Jan 10;6(1):
e00178. doi: 10.1097/BS9.0000000000000178. PMID: 38213825; PMCID: PMC10781138.
34. Law N, Logan C, Taplitz R. EBV Reactivation and Disease in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients and Its Impact on HSCT Outcomes. Viruses. 2024 Aug
14;16(8):1294. doi: 10.3390/v16081294. PMID: 39205268; PMCID: PMC11359191.
35. Papalexandri A, Gavriilaki E, Vardi A, et al. Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes. Int J Mol Sci. 2023
Nov 7;24(22):16029. doi: 10.3390/ijms242216029. PMID: 38003218; PMCID: PMC10671524.
36. Mak JWY, Law AWH, Law KWT, et al. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era. World J Gastro-
enterol. 2023 Sep 7;29(33):4942-4961. doi: 10.3748/wjg.v29.i33.4942. PMID: 37731995; PMCID: PMC10507505.
37. Ji CY, Gu MM, Huang L, et al. Chronic hepatitis E: The neglected liver killer, Hepatobiliary & Pancreatic Diseases International, 2025, https://doi.org/10.1016/j.hbpd.2025.09.006.
38. Randi BA, Higashino HR, Silva VPD, et al. COVID-19 in hematopoietic stem-cell transplant recipients: A systematic review and meta-analysis of clinical characteristics and outcomes. Rev
Med Virol. 2023 Nov;33(6): e2483. doi: 10.1002/rmv.2483. Epub 2023 Oct 4. PMID: 37794598.
39. El Chaer, Firas et al. American Society of Transplantation and Cellular Therapy Series: #7 – Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.
Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, Volume 29, Issue 12, 730 – 738
40. Selby PR, Warner MS, Peake SL, et al. Optimizing antifungal prophylaxis in allogeneic stem cell transplantation: A cohort study of two different approaches. Transpl Infect Dis. 2022 De-
c;24(6):e13988. doi: 10.1111/tid.13988. Epub 2022 Nov 15. PMID: 36349869; PMCID: PMC10909427.
41. Stemler J, Mellinghoff SC, Khodamoradi Y, et al. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the
Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO), Journal of Antimicrobial Chemotherapy, Volume 78, Issue 8, August
2023, Pages 1813–1826, https://doi.org/10.1093/jac/dkad143
42. Noah Rosenberg, Matthew Weinstock, Carolyn D Alonso; Rates of Trimethoprim-Sulfamethoxazole Versus Alternative Pneumocystis Prophylaxis Agents in Patients Undergoing Hematopo-
ietic Stem Cell Transplantation. Blood 2024; 144 (Supplement 1): 7378. doi: https://doi.org/10.1182/blood-2024-199778
43. Chiu CY, Ching PR. Incidence of Pneumocystis Pneumonia in Immunocompromised Patients without Human Immunodeficiency Virus on Intravenous Pentamidine Prophylaxis: A Systema-
tic Review and Meta-Analysis. J. Fungi 2023, 9, 406. https://doi.org/10.3390/jof9040406
44. Reynolds G, Hall VG, Teh BW. Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy. Transpl
Infect Dis. 2023 Nov;25 Suppl 1(Suppl 1):e14109. doi: 10.1111/tid.14109. Epub 2023 Jul 29. PMID: 37515788; PMCID: PMC10909447.
45. Seth T, Melinkeri S, Dolai TK, et al. Preventing pneumococcal infections in patients with hematological malignancies: a review of evidence and recommendations based on modified Delphi
consensus. Front. Oncol. 15:1546641. doi: 10.3389/fonc.2025.1546641
46. Jiao X, Zhu J, Ding Y, et al. Effect of herpes zoster vaccine on patients after hematopoietic stem cell transplantation: a systematic review and meta-analysis. Virol J 22, 54 (2025). https://doi.
org/10.1186/s12985-025-02670-5
47. www.cdc.gov/vaccines/hcp/imz-schedules/adult-notes.html#note-covid-19
48. Miller PDE, Patel SR, Skinner R, et al. Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: Prepared on behalf of the British
society of blood and marrow transplantation and cellular therapy (BSBMTCT), the Children’s cancer and Leukaemia Group (CCLG), and British Infection Association (BIA), Journal of
Infection, Volume 86, Issue 1, 2023,1-8. https://doi.org/10.1016/j.jinf.2022.11.005.